Abstract:in non- ZM exosomes. ZM exosomes transferred to non–ZM fusion glio- blastoma cells and normal human astrocytes altered gene expression and induced mesenchymal–epithelial transition.The uptake of ZM exosomes induced an exosome-dependent phenotype defined by glioblastoma cell migration and invasion, neurosphere growth and angiogenesis. Additionally, ZM exosomes conferred temozolomide resistance to the glioblastoma cells. Exosomes-derived ZM fusion network proteins targeted multiple pro-onco- genic effectors in recipient cells within the glioblastoma microenvironment. Our findings show how exosomes mediate the aggressive character of glio- blastoma and how ZM fusion can aggravate it, with possible implications for the foundation of gene fusion–based therapy for managing glioblastoma. 4 cases per 100,000 people per year. Gliomas, like many tumours, are thought to rely primarily upon aerobic glycolysis for energy production. However, high levels of glycolysis have been identified in brain tumours through the study of cells that have adapted to culture conditions (Michelakis et al. Sci Trans Med 2010); cells that have been cultured in the absence of serum have been shown to retain their origi- nal characteristics and are more suitable for chemical and genetic screen-ing (Pollard et al. Cell Stem Cell 2008). Our findings demonstrate that primary-cultured human glioma cells grown under serum-free conditions require fatty acid oxidation to maintain respiratory and proliferative activ- ity. Specifically, enzymes required for fatty acid oxidation are observed in cells within human glioblastoma tissue, fatty acid oxidation is the primary contributor to respiratory activity in cells isolated from human glioma, and this metabolic pathway is a limiting factor in the proliferation of human and mouse glioma cells cultured in the absence of serum. Moreo-ver, pharmacological inhibition of fatty acid oxidation, using etomoxir, prolongs survival in a syngeneic mouse model of malignant glioma. Finally, we find that transcriptional upregulation of genes whose products play a role in fatty acid oxidation is significantly associated with lower survival in patients with low-grade glioma. Since fatty acid oxidation enzymes are present and functional in glioma tissues, this metabolic pathway could potentially be targeted to reduce energy production and cellular prolif- eration to provide therapeutic benefit to patients with malignant glioma. While there are currently several dozen under active clinical investigation for the treatment of glioma, there is a clear unmet need in this patient group and our data provide an entirely new pathway to target for the treatment of this cancer. optical imaging and uptake assays. Changes in molecular signaling were further analyzed by quantitative PCR, western blot, immunostaining and GTPase activation assay. RESULTS: Introduction of IDH1 mutations led to robust changes in the plasma membrane, which is demonstrated by increased membrane ruffling, lamellipodia formation, enhancement in endocytosis (>27x increase endocytosis index) and cellular migration (>2x increase in travel distance). Up-regulation of endocytosis/endosomal markers further demonstrated that varies endocytosis mechanisms were activated, such as caveolin, clathrin, Rab5 and EEA1 (over 1.9x, 14x, 5.0x and 4.3x increase, respectively). In addition, the endocytosis is related to the activation of Rac1, as Rac1 phosphorylation increased by 1.5x in mutant cells. Inhibition on Rac1 pathway extensively limited endocytosis (>89% reduction as endocytosis index) in IDH1 mutant cells. CONCLUSION: Our findings highlight a novel molecular mechanism that is possibly involved in IDH1 -associated oncogenesis. The observed enhancement of endocytosis and cellular motility suggests this as a potential mechanism related to a more infiltrative and pos- sibly more aggressive phenotype during cancer progression. The unexpected finding of Rac1 activation suggests the potential for a novel therapeutic tar- get for glioma treatment. is a novel characteristic of malignan- cies. Identifying the vulnerability of lipid alteration in tumor cells provides a new opportunity to treat cancer. Here, we unraveled that glioblastoma (GBM) patients containing high levels of lipid droplets (LDs), special orga-nelles storing cholesterol esters in cells, presented poor survival. We found that LDs largely formed in tumor tissues from GBM patients, but rarely in low grade of gliomas and normal brain tissues, demonstrating that LDs might serve as a novel diagnostic biomarker and prognostic marker for GBM. We further revealed that sterol O-acyltransferase 1 (SOAT1), the key enzyme controlling cholesterol esterification and LD formation, is highly expressed and correlated with LD prevalence in tumor tissues from GBM patients. Genetic or pharmacologic inhibition SOAT1 using avasimibe, a phase III clinical trial drug in human atherosclerosis patients, significantly suppressed GBM growth and prolongs survival in xenograft models. Moreover, we found that inhibition of SOAT1 suppressed sterol regulatory element-binding protein-1 (SREBP-1), a key transcription factor playing a central role in lipid synthesis, which underlies the molecu- lar mechanism of targeting SOAT1-mediated GBM growth suppression. In summary, our data demonstrate that LDs/cholesterol esters uniquely formed in tumor tissues provides an ideal target to specifically inhibit GBM cells whereas sparing normal brain tissues, and reveal that blocking cholesterol storage via targeting SOAT1 represents a promising strategy for GBM treatment. However, tumour recurrence is common with acquired resistance to both therapies. Novel drug combinations are desperately needed to improve outcomes for patients with GBM. Targeting nicotinamide metabo- lism in GBM may be one way to achieve this. Cancer cells need to maintain high levels of intracellular NAD to fuel metabolic reactions, maintain redox balance through glutathione synthesis, promote proliferation through reg-ulation of sirtuin activity, and enable DNA repair through PARP activa- tion. Since TMZ is a DNA damaging agent, inhibition of NAD synthesis could improve its efficacy. Moreover, the TCGA data suggests that elevated expression of enzymes involved in nicotinamide metabolism are predictive of survival in patients with GBM. RESULTS: We report that GBM cells are highly sensitive to the NAMPT inhibitor FK866. We observe that sen-sitivity to FK866 correlates with the expression of NAMPT, NT5E and NAPRT. Cells expressing NAPRT can utilise nicotinic acid to synthesise NAD, and cells expressing NT5E can convert extracellular NMN in to nic- otinamide riboside to fuel NAD synthesis. We have shown that inhibition or knockdown of NT5E sensitises GBM cells to FK866 and TMZ. NT5E null cells exhibit decreased proliferation, increased activation of apoptosis and increased cell death in the presence of TMZ and FK866. These effects are enhanced when the two drugs are combined. Finally, we show that FK866 rapidly depletes NAD/NADH levels in GBM cells, and that knockdown of NT5E lowers NAD/NADH levels as well. CONCLUSION: The use of FK866 and TMZ in combination could be explored to combat GBM recur- rence and improve patient survival, stratified on the basis of NT5E and NAPRT status.

Glioblastoma Cells Counteract PARP Inhibition through Pro-Survival Induction of Lipid Droplets Synthesis and Utilization

Abstract LB272: Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma multiforme

CBMT-29. PROMOTING FATTY ACID STORAGE BY DIACYLGLYCEROL-ACYLTRANSFERASE 1 PROTECTS GLIOBLASTOMA AGAINST OXIDATIVE STRESS AND MAINTAINS LIPID HOMEOSTASIS FOR RAPID TUMOR GROWTH

RECQ1 Promotes Stress Resistance and DNA Replication Progression Through PARP1 Signaling Pathway in Glioblastoma

Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma

Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells

Tmet-37. Targeting Lipid Mediated Non-Canonical Cell Death In Malignant Glioma

TMET-05. INCREASING GLUTAMINE UPTAKE-LIPOGENESIS AXIS PROMOTES TUMOR RESISTANCE TO LYSOSOME INHIBITION

PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway

Drug-Induced Reorganisation of Lipid Metabolism Limits the Therapeutic Efficacy of Ponatinib in Glioma Stem Cells

Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress.

Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma

CBIO-07. LIPID DROPLETS, A NOVEL DIAGNOSTIC BIOMARKER AND METABOLIC TARGET IN GLIOBLASTOMA

Olaparib: A Chemosensitizer for the Treatment of Glioblastoma

Metabolic reprogramming of poly(morpho)nuclear giant cells determines glioblastoma recovery from doxorubicin-induced stress

Lipid Droplets, A Novel Metabolic Target In Glioblastoma

PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo

Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma

GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment

Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells

Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells